Delphia Therapeutics is a Cambridge, Massachusetts oncology biotechnology company pioneering "activation lethality," a precision-medicine approach that targets cancer cells' vulnerability to oncogene overactivation by selectively over-activating cancer-linked signaling until tumor cells can no longer survive. - View it on GitHub